The Influence of Cyclandelate on Ca++ Translocation in Human Platelets

Akkerman, J. W. N.; Hoven, W. E. van den

doi:10.2165/00003495-198700332-00010

Cited by 7 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…propranolol and metoprolol, have convincingly been shown to have migraine prophylactic activity (1, 2). Cyclandelate inhibits provoked calcium overload in neurones, calcium‐induced contraction of vascular smooth muscle cells and platelet aggregation induced by thrombin, PAF and adenosine (3–7). This pharmacological pattern made prophylactic action in migraine possible.…”

Section: Introductionmentioning

confidence: 99%

Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study

Krupp²,

Schmitt³

et al. 2001

Cephalalgia

View full text Add to dashboard Cite

The prophylactic action of cyclandelate was investigated in a multicentre, randomized, placebo-controlled, parallel group study. A 4-week baseline period was followed by a 4-week placebo phase and a 16-week treatment period with either 1600 mg cyclandelate or placebo. Patients (n = 251) with two to six migraine attacks/month were randomized. Neither the primary study endpoint (reduction of migraine days from baseline to the last 28 days) nor most of the secondary endpoints (reduction in the number of migraine attacks, severity or duration of attacks, frequency of autonomic disturbances, medication for treatment of attacks) showed a difference between cyclandelate and placebo. Cyclandelate, however, was superior to placebo in a global impression of efficacy rated by the patients and the treating physicians. Both treatments were well tolerated. In conclusion, cyclandelate was not superior to placebo in the prophylaxis of migraine with regard to parameters usually used in migraine prophylaxis trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study

Krupp²,

Schmitt³

et al. 2001

Cephalalgia

View full text Add to dashboard Cite

show abstract

Wirkungen von Cyclandelat auf das ZNS — Eine doppelblinde, placebo-kontrollierte Studie an gesunden Probanden

et al. 1991

View full text Add to dashboard Cite

The effect of cyclandelate (Natil) on the CNS was tested in a double-blind, placebo-controlled pilot study on 48 healthy males using a single oral dosage of 1200 mg. The EEG was evaluated quantitatively by spectral analysis before and one hour as well as two and a half hours after drug or placebo administration under resting conditions and while performing a test of mental arithmetic. Under resting conditions the power in the alpha 2 frequency band of the signals from the frontal and central recordings was increased in the cyclandelate group in comparison to the placebo group. This effect was still observed two and a half hours after drug intake. Under the condition of mental arithmetic no drug related effect was observed in the EEG. The cyclandelate induced increase of spectral power in the alpha 2 frequency band under resting conditions demonstrates a general effect of cyclandelate on the CNS. The results are discussed with respect to the known age related decrease of spectral power in the alpha frequency band. The established effect of cyclandelate in young healthy subjects calls for a study with chronic treatment in elderly subjects or patients with cognitive deficits.

show abstract

Cyclandelate

2016

Meyler's Side Effects of Drugs

View full text Add to dashboard Cite

The Influence of Cyclandelate on Ca++ Translocation in Human Platelets

Cited by 7 publications

References 9 publications

Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study

Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study

Wirkungen von Cyclandelat auf das ZNS — Eine doppelblinde, placebo-kontrollierte Studie an gesunden Probanden

Cyclandelate

Contact Info

Product

Resources

About